影像与血浆生物标志物预测上皮性卵巢癌贝伐珠单抗反应的相关性
该研究为GOG-218的辅助分析,纳入1249例有影像测量数据的上皮性卵巢癌患者,用Hounsfield单位计算皮下脂肪密度(SFD)和内脏脂肪密度(VFD),评估其与总生存(OS)及贝伐珠单抗(bev)疗效的关系。结果显示高SFD和高VFD均与死亡风险增加相关,高VFD在安慰剂组中预示更差生存,但在bev组中无此效应,提示高VFD可能是bev反应的预测标志物。
要点
- 高SFD和高VFD均与上皮性卵巢癌患者死亡风险增加独立相关。
- 高VFD在安慰剂组中预示更差OS,但在贝伐珠单抗组中未见该负面效应。
- 高VFD患者可能更可能从初始贝伐珠单抗治疗中获益。
核心结论
- 高VFD和高SFD对上皮性卵巢癌患者具有负面预后影响。
- 高VFD似乎是贝伐珠单抗反应的预测标志物,高VFD患者可能更可能从初始贝伐珠单抗治疗中获益。
研究设计与样本
- GOG-218的辅助分析,纳入1249例(67%)有影像测量数据的上皮性卵巢癌患者。
- 利用Hounsfield单位(HU)计算皮下脂肪密度(SFD)和内脏脂肪密度(VFD)。
- 采用比例风险模型评估SFD和VFD与总生存(OS)的关联。
主要发现
- SFD每增加1个标准差,死亡HR为1.12(95% CI: 1.05-1.19,p=0.0009)。
- VFD每增加1个标准差,死亡HR为1.13(95% CI: 1.05-1.20,p=0.0006)。
- 安慰剂组中高VFD每增加1个标准差死亡HR为1.22(95% CI: 1.09-1.37,p=0.025)。
- 贝伐珠单抗组中高VFD每增加1个标准差死亡HR为1.01(95% CI: 0.90-1.14),未见效应。
- VFD低组中位OS在安慰剂与贝伐珠单抗分别为45个月与47个月;VFD高组分别为36个月与42个月。
临床怎么用
- 影像测量的VFD和SFD可作为上皮性卵巢癌的预后评估指标。
- 高VFD患者可能优先考虑含贝伐珠单抗的初始治疗方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Increasing measures of adiposity have been correlated with poor oncologic outcomes and a lack of response to anti-angiogenic therapies. Limited data exists on the impact of subcutaneous fat density (SFD) and visceral fat density (VFD) on oncologic outcomes. This ancillary analysis of GOG-218, evaluates whether imaging markers of adiposity were predictive biomarkers for bevacizumab (bev) use in epithelial ovarian cancer (EOC). PATIENTS AND METHODS: There were 1249 patients (67%) from GOG-218 with imaging measurements. SFD and VFD were calculated utilizing Hounsfield units (HU). Proportional hazards models were used to assess the association between SFD and VFD with overall survival (OS). RESULTS: Increased SFD and VFD showed an increased HR for death (HR per 1-SD increase 1.12, 95% CI:1.05-1.19 p = 0.0009 and 1.13, 95% CI: 1.05-1.20 p = 0.0006 respectively). In the predictive analysis for response to bev, high VFD showed an increased hazard for death in the placebo group (HR per 1-SD increase 1.22, 95% CI: 1.09-1.37; p = 0.025). However, in the bev group there was no effect seen (HR per 1-SD increase: 1.01, 95% CI: 0.90-1.14) Median OS was 45 vs 47 months in the VFD low groups and 36 vs 42 months in the VFD high groups on placebo versus bev, respectively. CONCLUSION: High VFD and SFD have a negative prognostic impact on patients with EOC. High VFD appears to be a predictive marker of bev response and patients with high VFD may be more likely to benefit from initial treatment with bev.
引用
- Buechel ME, Enserro D, Burger RA, et al. Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC). Gynecol Oncol. 2021. PMID: 33712274. doi:10.1016/j.ygyno.2021.02.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。